Ojjaara Tablet
Product Images NDC 81864-103

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Ojjaara (NDC 81864-103). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glaxosmithkline Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Momelotinib Dihydrochloride Monohydrate Chemical Structure (Ojjaara Spl Graphic 01)

Chemical structure diagram of Momelotinib, the active ingredient in Ojjaara. The structure includes aromatic rings and functional groups with annotations for hydrochloride and water components (2HCl and H2O).*

FDA Label Image

Figure 1 (Ojjaara Spl Graphic 02)

A bar chart comparing the percentage of patients achieving 50% or greater reduction in symptoms for Ojjaara 200 mg QD versus Danazol 300 mg BID. Symptoms listed along the x-axis include night sweats, pain under left rib, pruritus, early satiety, abdominal discomfort, bone pain, and fatigue. The y-axis represents the percentage of patients. Ojjaara shows higher response rates across symptoms compared to Danazol, with patient numbers indicated (Ojjaara n=130, Danazol n=65). Baseline mean and median values are provided below the axis for each symptom.*

FDA Label Image

Figure 2 (Ojjaara Spl Graphic 03)

A waterfall chart showing percent change from baseline in a subset of patients with anemia, comparing Ojjaara (Momelotinib) and Ruxolitinib. The y-axis represents percentage change, ranging from -100% to over 100%, with a horizontal line marking a 35% decrease. Dark bars represent Ojjaara and light bars represent Ruxolitinib.*

FDA Label Image

Ojjaara 100 mg Tablet 30 Count Label (Ojjaara Spl Graphic 04)

Ojjaara 100 mg (momelotinib) tablets packaging label showing product name, strength, dosage form, and quantity of 30 tablets. The label includes handling instructions, storage conditions, manufacturer (GlaxoSmithKline LLC), and NDC 81864-103-30. It notes the tablet is to be swallowed whole and provides safety and trademark information.*

FDA Label Image

Ojjaara 150 mg Tablet 30 Count Label (Ojjaara Spl Graphic 05)

Label for Ojjaara (momelotinib) tablets, 150 mg strength, oral dosage form. The label shows 30 tablets per bottle, manufactured by GlaxoSmithKline LLC. It includes storage instructions, safety warnings about swallowing tablets whole, and other regulatory information. The product is prescription only.*

FDA Label Image

Ojjaara 200 mg Tablet 30 Count Label (Ojjaara Spl Graphic 06)

Ojjaara 200 mg tablets packaging label showing the oral tablet dosage form of momelotinib. The label includes the proprietary and generic names, strength of 200 mg, package count of 30 tablets, and manufacturer GlaxoSmithKline LLC. Additional details about storage conditions and usage instructions are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.